<style face="normal" font="default" size="100%">1383 Preclinical characterization of D3L-002, a novel cancer immunotherapy bispecific antibody that elicits potent anti-tumor efficacy via co-blocking TIGIT and PVRIG</style>

Drupal-HighWire